Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Crossref · journal-article

Effects of a balanced cannabinoid extract on agitation and cognition in older adults with moderate Alzheimer's disease dementia: a randomized clinical trial protocol

Tereza Raquel Xavier Viana, Gabriela Cabett Cipolli, Isabela Monteiro Toniasso, Danielle Aparecida Oliveira Pontes, Eduarda Gomes da Costa Onofre, Flávia Savietto de Camargo, Ivan Aprahamian, José Eduardo Martinelli

Geriatrics Gerontology and Aging · 2026 · Band 20

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Objectives: Alzheimer's disease (AD) is often associated with agitation, which negatively impacts patients' quality of life and increases the burden on caregivers. This protocol aims to investigate the effects of a balanced extract of Cannabis sativa, containing cannabidiol (CBD) and tetrahydrocannabinol (THC), on agitation and cognition in older adults with moderate-stage AD dementia. Methods: Randomized, controlled, prospective, open-label, parallel-group clinical trial lasting three months. A total of 124 participants aged 60 years or older, undergoing geriatric outpatient follow-up, will be included and allocated to two groups: a control group, which will receive the standard of care (SOC), and an intervention group, which will receive SOC plus a balanced extract of Cannabis sativa containing 300 mg CBD and 180 mg THC. The primary outcome will be reduction in agitation, assessed by the Cohen-Mansfield Agitation Inventory. Secondary outcomes include cognition (Addenbrooke's Mini-Cognitive Examination), neuropsychiatric symptoms (Neuropsychiatric Inventory), functionality (Functional Stage Scale and Pfeffer Functional Activities Questionnaire), and adverse events. Placebo control was ruled out for ethical reasons. The study will follow international ethical guidelines, with consent from participants’ legal proxies and supervision by an independent data monitoring committee. The protocol was approved by an ethics committee and registered with ReBEC. Expected results: A reduction in agitation is expected, with possible positive effects on cognition, neuropsychiatric symptoms, and functionality, while maintaining an acceptable safety profile. Relevance: This study may contribute to the use of cannabinoids as an adjunctive strategy in the management of behavioral symptoms of AD dementia in geriatric practice.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Tereza Raquel Xavier Viana, Gabriela Cabett Cipolli, Isabela Monteiro Toniasso, Danielle Aparecida Oliveira Pontes, Eduarda Gomes da Costa Onofre, Flávia Savietto de Camargo, Ivan Aprahamian, José Eduardo Martinelli
Quelle
Geriatrics Gerontology and Aging
Publikation
2026-08-10
Band / Ausgabe
20
Seiten
Nicht angegeben
ISSN / ISBN
2447-2115, 2447-2123
Zitationen
0 laut Crossref
Referenzen
25 hinterlegt

Zitieren

Zitierfähiger Nachweis

Tereza Raquel Xavier Viana, Gabriela Cabett Cipolli, Isabela Monteiro Toniasso, Danielle Aparecida Oliveira Pontes, Eduarda Gomes da Costa Onofre, Flávia Savietto de Camargo, Ivan Aprahamian, José Eduardo Martinelli (2026). Effects of a balanced cannabinoid extract on agitation and cognition in older adults with moderate Alzheimer's disease dementia: a randomized clinical trial protocol. Geriatrics Gerontology and Aging, 20. https://doi.org/10.53886/gga.e0000467_en
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1